Pharmafile Logo
Pharmafocus logo
Advanced Search

Alzheimer’s

Showing 15 posts of 148 posts found.

satu1028-pano_1024_px

EMA set to also revise guidelines of Alzheimer’s trials

February 28, 2018
Medical Communications Alzheimer's, EMA, FDA, biotech, drugs, pharma, pharmaceutical

The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News
abbviehqe_004_low

AbbVie turns to tau for Alzheimer’s in $1.1bn deal

February 21, 2018
Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …

News
fda_building_web

FDA weighs up divisive change to Alzheimer’s drug assessment

February 16, 2018
Medical Communications Alzheimer's, FDA, biotech, drugs, pharma, pharmaceutical

Alzheimer’s disease (AD) is an area badly in need of a treatment, the problem is that this prospect seems to …

News
biogen_austria_238

Biogen shares hit by key Alzheimer’s drug concerns

February 15, 2018
Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

News
merckincweb

MSD shuts down Phase 3 trial in prodromal Alzheimer’s

February 14, 2018
Research and Development Alzheimer's, MSD, pharma, verubecestat

Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a …

News
bi_microparts_image

Boehringer terminates Alzheimer’s candidate after Phase 2 failure

February 12, 2018
Research and Development, Sales and Marketing Alzheimer's, Boehringer Ingelheim, dementia, pharma

Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten

It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …

News
blood_testing

New blood test for Alzheimer’s offers hope

February 1, 2018
Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical

To say January was a bleak month for Alzheimer’s research would be something of an understatement: Pfizer ducked out of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate

As we come to the end of January, it’s Friday again – time for another rundown of the top ten …

News
aging_-_hand

Senescent cell findings provides Parkinson’s treatment clue

January 25, 2018
Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical

Senescent cells are the dormant state that cells shift to in response to certain stressors, it is thought that they …

News
old_man_bar

Amyloid pathway doubts after latest Alzheimer’s failure

January 25, 2018
Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical

There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
old_man_bar

Another Alzheimer’s drug bites the dust in P3

January 12, 2018
Medical Communications, Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical

It’s been a terrible week for Alzheimer’s disease research, after Pfizer shuttered its neuroscience unit and

News
hands-981400_960_720

New project examining FDA-approved drugs for Alzheimer’s, worries over research remains

January 10, 2018
Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical

It’s been a gloomy period for research into Alzheimer’s disease treatments in the last week, Pfizer announced it would be …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024